Free Trial

Oncobiologics (OTLK) Competitors

Oncobiologics logo
$1.89 +0.03 (+1.61%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$1.93 +0.04 (+2.12%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OTLK vs. PRQR, NGNE, CRDF, MDWD, EPRX, SOPH, INBX, YMAB, ACIU, and VOR

Should you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include ProQR Therapeutics (PRQR), Neurogene (NGNE), Cardiff Oncology (CRDF), MediWound (MDWD), Eupraxia Pharmaceuticals (EPRX), SOPHiA GENETICS (SOPH), Inhibrx Biosciences (INBX), Y-mAbs Therapeutics (YMAB), AC Immune (ACIU), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry.

Oncobiologics vs. Its Competitors

Oncobiologics (NASDAQ:OTLK) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

ProQR Therapeutics has higher revenue and earnings than Oncobiologics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncobiologicsN/AN/A-$75.37M-$0.91-2.08
ProQR Therapeutics$20.46M11.31-$30.04M-$0.35-6.29

Oncobiologics currently has a consensus target price of $9.60, indicating a potential upside of 407.94%. ProQR Therapeutics has a consensus target price of $8.00, indicating a potential upside of 263.64%. Given Oncobiologics' higher possible upside, research analysts clearly believe Oncobiologics is more favorable than ProQR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncobiologics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
ProQR Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13

In the previous week, ProQR Therapeutics had 3 more articles in the media than Oncobiologics. MarketBeat recorded 5 mentions for ProQR Therapeutics and 2 mentions for Oncobiologics. ProQR Therapeutics' average media sentiment score of 0.22 beat Oncobiologics' score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oncobiologics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ProQR Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Oncobiologics has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500.

Oncobiologics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -157.04%. Oncobiologics' return on equity of 0.00% beat ProQR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
OncobiologicsN/A N/A -271.12%
ProQR Therapeutics -157.04%-53.49%-22.07%

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 4.8% of Oncobiologics shares are owned by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

ProQR Therapeutics beats Oncobiologics on 12 of the 16 factors compared between the two stocks.

Get Oncobiologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OTLK vs. The Competition

MetricOncobiologicsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$62.44M$2.87B$5.50B$8.95B
Dividend YieldN/A2.45%5.25%4.04%
P/E Ratio-2.0820.8026.9720.11
Price / SalesN/A286.31425.92119.81
Price / CashN/A41.1936.8257.86
Price / Book-0.617.487.985.56
Net Income-$75.37M-$55.04M$3.16B$248.40M
7 Day Performance10.53%2.44%2.36%4.67%
1 Month Performance-0.53%1.90%2.15%6.64%
1 Year Performance-76.08%4.35%33.78%21.31%

Oncobiologics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OTLK
Oncobiologics
1.6577 of 5 stars
$1.89
+1.6%
$9.60
+407.9%
-76.0%$62.44MN/A-2.0820
PRQR
ProQR Therapeutics
2.1054 of 5 stars
$2.04
flat
$8.00
+292.2%
+32.5%$214.63M$20.46M-5.83180News Coverage
NGNE
Neurogene
3.6125 of 5 stars
$14.95
-7.5%
$46.17
+208.8%
-44.9%$213.19M$930K-3.4490
CRDF
Cardiff Oncology
1.6864 of 5 stars
$3.15
flat
$9.88
+213.5%
+77.5%$209.57M$680K-3.4220News Coverage
Analyst Forecast
MDWD
MediWound
1.619 of 5 stars
$19.37
+0.6%
$31.80
+64.2%
+0.1%$209.39M$20.22M-9.2780
EPRX
Eupraxia Pharmaceuticals
2.3829 of 5 stars
$5.76
+8.7%
$11.00
+91.0%
+123.6%$207.13MN/A-7.5829News Coverage
Gap Up
High Trading Volume
SOPH
SOPHiA GENETICS
2.3499 of 5 stars
$3.10
+0.3%
$7.00
+125.8%
-21.2%$206.74M$65.17M-3.10520News Coverage
Positive News
INBX
Inhibrx Biosciences
0.9893 of 5 stars
$14.27
-1.1%
N/A+46.5%$206.63M$200K0.12166News Coverage
YMAB
Y-mAbs Therapeutics
3.2789 of 5 stars
$4.51
-4.0%
$15.60
+245.9%
-62.7%$204.21M$87.68M-7.05150
ACIU
AC Immune
2.7562 of 5 stars
$2.03
+1.0%
$12.00
+491.1%
-40.5%$203.83M$28.30M-3.50140
VOR
Vor Biopharma
3.9425 of 5 stars
$1.62
+52.8%
$5.63
+247.4%
+164.9%$202.44MN/A-0.98140Options Volume
Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:OTLK) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners